Europe’s pharma industry sees a drop of 11.1% in deal activity in March 2019

25 April 2019 (Last Updated April 25th, 2019 14:41)

Europe’s pharma industry sees a drop of 11.1% in deal activity in March 2019

Europe’s pharma industry saw a drop of 11.1% in deal activity during March 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 24 pharma industry deals worth $2.86bn were announced for the region in March 2019, against the 12-month average of 27 deals.

Of all the deal types, M&A saw most activity in March 2019 with 11 transactions, representing a 45.8% share for the region.

In second place was venture financing with 11 deals, followed by private equity deals with two transactions, respectively capturing a 45.8% and 8.3% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in Europe’s pharma industry with $1.93bn, while private equity and venture financing deals totalled $830.01m and $107.06m, respectively.

Europe pharma industry deals in March 2019: Top deals

The top five pharma deals accounted for 96.2% of the overall value during March 2019.

The combined value of the top five pharma deals stood at $2.75bn, against the overall value of $2.86bn recorded for the month. The top announced pharma deal tracked by GlobalData in March 2019 was Fujifilm’s $890m acquisition of Biogen Denmark Manufacturing.

In second place was the $877m acquisition of Nightstar Therapeutics by Biogen and in third place was Waypoint Group Holdings’ $830.01m private equity deal with Stallergenes Greer.

The $105m asset transaction with GW Research by Biohaven Pharmaceutical Holding and Pfizer’s acquisition of Vivet Therapeutics for $51.09m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.